ArticleWorld journal of gastroenterology2026
Efficacy and safety of sequential hyperthermic intraperitoneal chemotherapy following surgery for pathological T staging 4 gastric cancer.
Article in World journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPeritoneal metastasis influences prognosis and quality of life in patients with gastric cancer. The efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) as postoperative adjuvant therapy for advanced gastric cancer remains unclear.
aimTo evaluate the efficacy and safety of HIPEC plus postoperative adjuvant chemotherapy (AC) for locally advanced gastric cancer.
methodsWe analyzed 225 patients with gastric cancer who underwent radical surgery, categorized by those receiving HIPEC plus AC (HIPEC + AC group) and those receiving AC alone (AC group). Treatments were administered every other day, for a total of one to three sessions. Overall survival, disease-free survival (DFS), disease-free interval, peritoneal metastasis-free interval, and safety outcomes were compared between the groups. Survival analysis was performed using Kaplan-Meier curves with log-rank tests for group comparisons.
resultsIn total, 225 patients with non-metastatic pathological T staging 4 gastric adenocarcinoma were included (HIPEC + AC group,
conclusionHIPEC plus postoperative AC improves DFS and reduces peritoneal metastasis risk in non-metastatic pathological T staging 4 gastric adenocarcinoma without increasing adverse events, confirming its safety and efficacy in preventing recurrence and dissemination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.